Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 1 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Breast 4Gynecologic 2Head & Neck 1Genitourinary 1CNS 1

Conditions

Breast Neoplasms 311Carcinoma, Non-Small-Cell Lung 276Neoplasms 255Prostatic Neoplasms 216Colorectal Neoplasms 196Lung Neoplasms 153Multiple Myeloma 148Neoplasm Metastasis 135Ovarian Neoplasms 126Leukemia, Myeloid, Acute 123Pancreatic Neoplasms 116Melanoma 102Squamous Cell Carcinoma of Head and Neck 97Recurrence 85Endometrial Neoplasms 82Carcinoma, Renal Cell 80Glioblastoma 78Lymphoma, Non-Hodgkin 77Stomach Neoplasms 73Precursor Cell Lymphoblastic Leukemia-Lymphoma 72Lymphoma 72Carcinoma, Hepatocellular 72Glioma 65Brain Neoplasms 65Uterine Cervical Neoplasms 63Sarcoma 63Head and Neck Neoplasms 63Triple Negative Breast Neoplasms 59Leukemia, Lymphocytic, Chronic, B-Cell 58Urinary Bladder Neoplasms 55

Interventions

abemaciclib 2Fulvestrant 2trastuzumab deruxtecan 1taxane 1ribociclib 1pertuzumab 1palbociclib 1exemestane 1elacestrant 1Trastuzumab 1Tamoxifen 1STX-478 1RAD1901 1Metformin 1Letrozole 1Imlunestrant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Breast Diseases × 30 days × Clear all
NCT05386108 2026-06-04

ELECTRA

Stemline Therapeutics, Inc.

Phase 1/2 Recruiting
73 enrolled
BreastCNS

Brain Diseases, Brain Neoplasms, Breast Diseases, Breast Neoplasms, Central Nervous System Diseases, Neoplasms, Neoplasms by Site, Central Nervous System Neoplasms

NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT07038369 2026-06-03

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Atavistik Bio, Inc

Phase 1 Active not recruiting
134 enrolled
BreastGenitourinaryGynecologic

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04784715 2026-05-22

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

AstraZeneca

Phase 3 Active not recruiting
1,157 enrolled 1 FDA
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡